Optimal scheduling of interleukin-12 and fractionated radiation therapy in the murine lewis lung carcinoma

Radiation Oncology Investigations

Volumn 6, Issue 2, 1998, Pages 71-80

  Teicher, Beverly A ^a,b   Ara, Gulshan ^b   Buxton, David ^b   Leonard, John ^c   Schaub, Robert G ^c  

^a ELI LILLY AND COMPANY   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c PFIZER INC   (United States)

Author keywords

Intereron ; Interleukin 12; Louis lung carcinoma; Radioscnsitization

Indexed keywords

RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 12;

ANIMAL EXPERIMENT; ARTICLE; CANCER RADIOTHERAPY; LEWIS CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIOSENSITIVITY; TREATMENT PLANNING;

ANIMALS; CARCINOMA, LEWIS LUNG; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERLEUKIN-12; MALE; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; RADIATION DOSAGE; TIME FACTORS;

EID: 0031923243     PISSN: 10657541     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1520-6823(1998)6:2<71::AID-ROI2>3.0.CO;2-E     Document Type: Article

References (39)

1. Banks RE, Patel PM, Selby PJ: Interleukin 12: A new clinical player in cytokine therapy. Br J Cancer 71:655-659, 1995.
2. Gazzinelli RT, Hieny S, Wynn TA, Wolf S, Sher A: Interleukin 12 is required for the T-lymphocyte-independent induction of interferon γ by an intracellular parasite and induces resistance in T-cell-deficient hosts. Proc Natl Acad Sci USA 90:6115-6119, 1993.
3. Locksley RM: Interleukin 12 in host defense against microbial pathogens. Proc Natl Acad Sci USA 90: 5879-5880, 1993.
4. Robertson M, Ritz J: Interleukin 12: Basic biology and potential applications in cancer treatment. The Oncologist 1:88-97, 1996.
5. Gately MK, Desai B, Wolitzky AG, Quinn PM, Dwyer CM, Podlaski FJ, Familletti PC, Sinigaglia F, Chizzonite R, Gubler U, Stern AS: Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J Immunol 147:874-882, 1991.
6. + T lymphocytes, and NK cells. J Immunol 149: 3495-3502, 1992.
7. Robertson MJ, Soiffer RJ, Wolf SF, Manley TJ, Donahue C, Young D, Hermann SH, Ritz J: Responses of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): Cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J Exp Med 175:779-788, 1992.
8. Gately MK, Wolitzky AG, Quinn PM, Chizzonite R: Regulation of human cytolytic lymphocyte responses by interleukin-12. Cell Immunol 143:127, 1992.
9. + NK cells. J Immunol 148:2429-2436, 1992.
10. Chan SH, Perussia B, Gupta JW, Kobayashi M, Pospisil M, Young HA, Wolf SF, Young D, Clark SC, Trinchieri G: Induction of interferon γ production by natural killer cell stimulatory factor: Characterization of the responding cells and synergy with other inducers. J Exp Med 173:869-879, 1991.
11. Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, Wolf SF, Gately MK: Antitumor and antimetastatic activity of Interleukin-12 against murine tumors. J Exp Med 178:1223-1230, 1993.
12. Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ, Gately MK, Wolf SF, Schreiber RD, Storkus WJ, Lotze MT: Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J Immunol 153:1697-1706, 1994.
13. Noguchi Y, Richards EC, Chen YT, Old LJ: Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc Natl Acad Sci USA 92:2219-2223, 1995.
14. Brunda M, Luistro L, Rumennik L, Wright R, Dvorozniak M, Aglione A, Wigginton J, Wiltrout R, Hendrzak J, Palleroni A: Antitumor activity of interleukin 12 in preclinical models. Cancer Chemother Pharmacol 38:S16-S21, 1996.
15. Fujiwara H, Hamaoka T: Antitumor and antimetastatic effects of interleukin 12. Cancer Chemother Pharmacol 38:S22-S26, 1996.
16. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J: Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 87:581-586, 1995.
17. Kedar E, Klein E: Cancer immunotherapy: Are the results discouraging? Can they be improved? Adv Cancer Res 59:245, 1992.
18. Seder RA, Gazzinelli R, Sher A, Paul WE: Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon γ production and diminishes interleukin 4 inhibition of such priming. Proc Natl Acad Sci USA 90:10188-10192, 1993.
19. Yoshida A, Koide Y, Uchijima M, Yoshida TO: IFN-γ induces IL-12 mRNA expression by a murine macrophage cell line, J774. Biochem Biophys Res Commun 198:857-861, 1994.
20. Gately MK, Warrier RR, Honasoge S, Carvajal DM, Faherty DA, Connaughton SE, Anderson TD, Sarmiento U, Hubbard BR, Murphy, M: Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-γ in vivo. Int Immunol 6:157-167, 1994.
21. Zeh III HJ, Hurd S, Storkus WJ, Lotze MT: Interleukin-12 promotes the proliferation and cytolytic maturation of immune effectors: Implications for the immunotherapy of cancer. J Immunother 14:155-161, 1993.
22. Caruso M, Pham-Nguyen K, Kwong Y, Xu B, Kosai K, Finegold M, Woo S, Chen S: Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc Natl Acad Sci USA 93:11302-11306, 1996.
23. Nishimura T, Watanabe K, Yahata T, Ushaku L, Ando K, Kimura M, Saiko I, Uede T, Habu S: Application of interleukin 12 to antitumor cytokine and gene therapy. Cancer Chemother Phamacol 38:S27-S34, 1996.
24. Brunda MJ: Interleukin-12. J Leuk Biol 55:280-288, 1994.
25. Teicher BA, Ara G, Menon K, Schaub RG: In vivo studies with interleukin-12 alone and in combination with monocyte-colony stimulating factor and/or fractionated radiation therapy. Int J Cancer 65:80-84, 1995.
26. Gohji K, Fidler I, Tsan R, Radinsky R, von Eschenbach A, Tsuruo T, Nakajima M: Human recombinant interferons-beta and -gamma decrease gelatinase production and invasion by human KG-2 renal-carcinoma cells. Int J Cancer 58:380-384, 1994.
27. r 92,000 type-IV collagenase (gelatinase A and B) gene expression by interferons alpha and gamma in human melanoma. Int J Cancer 58:582-586, 1994.
28. Norioka K, Mitaka T, Mochizuki Y, Hara M, Kawagoe M, Nakamura H: Interaction of Interleukin-1 and Interferon-γ on fibroblast growth factor-induced angiogenesis. Jpn J Cancer Res 85:522-529, 1994.
29. Hiscox S, Hallett MB, Puntis MCA, Jiang WG: Inhibition of cancer cell motility and invasion by interleukin-12. Clin Exp Metastasis 13:396-404, 1995.
30. Wigginton JM, Komschlies KL, Back TC, Franco JL, Brunda MJ, Wiltrout RH: Administration of Interleukin-12 with pulse Interleukin-2 and the rapid and complete eradication of murine renal carcinoma. J Natl Cancer Inst 88:38-43, 1996.
31. Lu L, Shen RN, Lin ZH, Aukerman SL, Ralph P, Broxmeyer HE: Anti-tumor effects of recombinant human macrophage colony-stimulating factor, alone or in combination with local irradiation, in mice inoculated with Lewis lung carcinoma cells. Int J Cancer 47:143-147, 1991.
32. Bonta IL, Ben-Efraim S: Involvement of inflammatory mediators in macrophage antitumor activity. J Leuk Biol 54:613-626, 1993.
33. Wolf SF, Sieburth D, Sypek J: Interleukin 12: A key modulator of immune function. Stem Cells 12:154-168, 1994.
34. Munn DH, Cheung NK: Antibody-dependent antitumor cytotoxicity by human monocytes cultured with recombinant macrophage colony-stimulating factor: Induction of efficient antibody mediated antitumor cytotoxicity not detected by isotope release assays. J Exp Med 170:511-526, 1989.
35. Aglietta M, Monzeglio C, Pasquino P, Carnino F, Ster AC, Gavosto F: Short-term administration of granulocyte-macrophage colony stimulating factor decreases hematopoietic toxicity of cytostatic drugs. Cancer 72: 2970-2973, 1993.
36. Miller AM: Hematopoietic growth factors in autologous bone marrow transplantation. Semin Oncol 20: 88-95, 1993.
37. Naparstek E, Ohana M, Greenberger JS, Slavin S: Continuous intravenous administration of rmGM-CSF enhances immune as well as hematopoietic reconstitution following syngeneic bone marrow transplantation in mice. Exp Hematol 21:131-137, 1993.
38. Steinman RM: The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9:271-296, 1991.
39. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 20:3539-3543, 1993.